A Phase 2 interventional study of standard therapy and activated recombinant human factor VII in Acquired Bleeding Disorder and Bleeding During/Following Surgery, sponsored by Novo Nordisk A/S. Completed at 46 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial is conducted in Asia, Europe and Oceania. The aim of this trial is to evaluate the efficacy of placebo and activated recombinant human factor VII in patients having undergone allogeneic or autologous stem cell transplantation.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: standard therapy · Drug: placebo
Procedure: standard therapy · Drug: activated recombinant human factor VII
Procedure: standard therapy · Drug: activated recombinant human factor VII
Procedure: standard therapy · Drug: activated recombinant human factor VII
Standard treatment of bleeding
Two days repeated treatment regimen - low dose administered i.v. (into the vein)
Two days repeated treatment regimen - medium dose administered i.v. (into the vein)
Two days repeated treatment regimen - high dose administered i.v. (into the vein)
Placebo
Effect on bleeding, defined as change in bleeding score
Transfusion requirements
Bleeding evaluation
Adverse events
The record gives a start of Apr 2001, a primary completion of Oct 2003 and a completion of Oct 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recombinant FVIIa